Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone after TEVAR for aortic dissection
NCT02523300Unknown
- Sponsor
- Changhai Hospital
- Start
- Oct 2015
- Primary completion
- Sep 2017
- Modality
- Orthosteric Ligands
01
Overview
Randomised, open-label trial of methylprednisolone in aortic dissection (2 arms), sponsored by Changhai Hospital. Primary endpoint: Aorta-related adverse events at 24 months. Status: unknown.
02
Drugs
methylprednisolone
03
Conditions
aortic dissection
Beyond the preview
Go deeper on NCT02523300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02523300.